Akkermansia Muciniphila : Promising results for insulin sensitivity Akkermansia Muciniphila As for Akkermansia Muciniphila , a bacterium claimed by trending supplement brand Pendulum to increase GLP-1 production, he says, Its a pretty promising microbe when it comes to insulin sensitivity, but Ive not seen any human clinical data about Akkermansia, GLP-1 production and weight loss. On its website, the company (which includes actress Halle Berry among its investors) links to animal research showing that Akkermansia Muciniphila increased GLP-1 production in mice on a high-fat diet
3.3 Liraglutide improves hepatic steatosis and fibrosis development in lipodystrophic mice Due to an inability to appropriately store lipids, individuals with lipodystrophies typically develop metabolic dysfunction-associated steatotic liver disease (MASLD) which often progresses to hepatic steatosis and fibrosis
This was accompanied by upregulation of FABP4 and HSL , alongside reduced receptor for advanced glycation end products ( RAGE ) expression, suggesting enhanced lipid turnover and improved adipocyte function
Clinical Profile of Exenatide To understand subsequent innovations, its helpful to summarize exenatides clinical profile (as the first GLP-1 RA): Efficacy: In trials, twice-daily exenatide (10 g BID) typically reduced HbAc by approximately 0.8%1.0% more than placebo by 30 weeks ( [61] ) ( [101] )
The SELECT cardiovascular outcomes trial, involving over 17,600 participants at high cardiovascular risk, found that semaglutide cut major cardiac events by 20% over nearly 3 years